インデックス付き
- Jゲートを開く
- Genamics JournalSeek
- アカデミックキー
- ジャーナル目次
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- SWBオンラインカタログ
- パブロン
- ジュネーブ医学教育研究財団
- ユーロパブ
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
Review Article Brexanolone: A Pharmacotherapy Approach in Post Partum Depression
Priyanka N, Shalini S
Postpartum depression is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered as a life-threatening condition in postpartum women’s. Brexanolone is an efficient drug approved for the first time by the USFDA on March 19, 2019 for immediate release through Intravenous route used for the treatment of postpartum depression (PPD). This review article is about the detailed information of Brexanolone includes its drug information, mechanism of action, pharmacokinetic and pharmacodynamics studies, side effects, drug prescribing detail. This article also includes the information about the postpartum depression- its epidemiology, etio-pathology, signs and symptoms, diagnostic pattern.